Navigation Links
Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
Date:5/15/2012

ornia San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

Dr. Rugo is a Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF), where she directs Breast Oncology and Clinical Trials Education.  Her research interests include innovative new therapies for women with advanced breast cancer, evaluation of special circulating cells to help understand response to therapy, complementary medicine, and supportive care.

Dr. Rugo is a member of the breast core committee of the Alliance for Clinical Trials in Oncology Network, where she is the principal investigator of CALGB 40502, a now fully accrued phase III trial comparing novel chemotherapy agents in the treatment of advanced breast cancer.  She is also an investigator in the Bay Area Spore at UCSF's Carol Franc Buck Breast Cancer Center and the principal investigator of a number of clinical trials testing new treatment approaches.  Dr. Rugo is an investigator and novel agent chaperone for ISPY2, an innovative multicenter neoadjuvant chemotherapy trial.  She has published many peer-reviewed papers and has given presentations on a variety of cancer-related topics, and is the breast section editor for Cancer.Net, a patient focused publication of the American Society of Clinical Oncology.

With a summa cum laude undergraduate degree from Tufts University, Dr. Rugo received her M.D. from the University of Pennsylvania School of Medicine and completed both a residency in internal medicine and a fellowship in hematology and oncology at the UCSF.  Additionally, she completed a two-year post-doctoral fellowship in immunology at Stanford University.

Mark A. Fletcher, Generex President & Chief Executive Officer, commented:  "The Antigen Express Team is gratified that physicians and scientists of the caliber of Drs. Miller and Rugo have agreed to join our SAB and proffer i
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 Biotechnology industry pioneer ... with financial software provider BlackLine Systems  and enterprise ... SAP ) for a webinar next week entitled "No ... from BlackLine and SAP to Help Keep Its Account Reconciliations ... http://photos.prnewswire.com/prnh/20061117/LAF027LOGO ) The webinar, geared at finance, ...
(Date:6/19/2013)... (PRWEB) June 18, 2013 A new ... materials, costs and other trends will highlight technical sessions ... California this fall. In its 33rd year, the three-day ... an exhibition of key suppliers, approximately 100 technical presentations ... SPIE, the international society for optics and photonics , ...
(Date:6/18/2013)... KONG, June 18, 2013 China Cord Blood ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its preliminary unaudited financial results for ... 2013 ended March 31, 2013. Fourth ... the fourth quarter of fiscal 2013 increased by 33.3% ...
(Date:6/18/2013)... 18, 2013 The human skin is the ... an important human body part. Similar to the liver, or ... to function, repair and grow. Recent reports from the mankatofreepress.com ... is just as important as other life supporting organs. The ... in skin cell reproduction, increase the appearance of skin, and ...
Breaking Biology Technology:Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 2Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 3Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations 4‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13Natural Acne Remedies Through Diet, Probiotic Action Shares New Insight on What Foods May Help Lead to Clear Skin 2
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ) ... the first patient received subcutaneous (SC) MabThera (rituximab), an ... Enhanze(™ technology (rHuPH20, recombinant human hyaluronidase). This ... Herceptin ® SC (trastuzumab), to enter a Phase ...
... Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... officer, will deliver the Company,s corporate presentation at Lippert/Heilshorn ... on Thursday, February 17, 2011 at 11:30 a.m. Eastern ... webcast with slide presentation at: www.transgenomic.com , or ...
... ROCKVILLE, Md., Feb. 15, 2011 Neuralstem, Inc. (NYSE ... business leader Stanley I. Westreich to its Board of ... comprised of a majority of independent directors. ... of Neuralstem,s Board of Directors and the Company,s Chief ...
Cached Biology Technology:Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 2Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 3Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab) 4Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 2Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17 3Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board 2Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board 3
(Date:6/19/2013)... of mammals and birds are threatened with extinction as a ... and colleagues from The Ohio State University in the US. ... exponential growth of the human population will continue to pose ... not appear to be a threshold above which population growth ... is published online in Springer,s journal, Human Ecology . ...
(Date:6/19/2013)... New York, NY, June 19, 2013 A ... Diabetes Research in Helmholtz Zentrum Mnchen, Germany, is ... autoantibodies and the risk of developing type 1 ... into possible preventions for the disease. The study, ... Progression to Diabetes in Children," was published today ...
(Date:6/19/2013)... offers further proof that the divergence of humans from ... was profoundly influenced by mutations to DNA sequences that ... The study, published June 9 in Nature Genetics ... of genes must play an important role in evolution ... in the proteins produced by genes. Indeed, human and ...
Breaking Biology News(10 mins):Are we pushing animals over the edge? 2New data on islet autoantibodies in young children defines early type 1 diabetes development 2New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3
... Bette Korber is part of an international team of ... trial of a mosaic HIV vaccine candidate. The vaccine ... causes AIDS by attempting to address one of the ... extensive genetic diversity. The team and its efforts ...
... UPTON, NY Scientists at the U.S. Department of ... have discovered a key difference in the way human ... unwanted proteins marked with a "kiss of death" ... critical difference, described in a paper published online October ...
... TAMPA, Fla., Sept. 22 Lockheed Martin (NYSE: ... new DNA analysis system that has potential to transform how ... in support of their missions. The prototype, called ... Biometric Consortium Conference special session on Rapid DNA. The ...
Cached Biology News:Consortium to design human trials of mosaic HIV vaccine 2Key difference in how TB bacteria degrade doomed proteins 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 3
... no longer need to perform time consuming and ... Mutation Surveyor, any found variants of the sample ... indicated in our mutation electropherogram as a sharp ... bi-directional analysis mode is over 99%, with sensitivity ...
...
... 220-240 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Biology Products: